No Data
No Data
Does TravelSky Technology (HKG:696) Have A Healthy Balance Sheet?
TRAVELSKY TECH: 2024 Annual Report
Lyon: Lowered TRAVELSKY TECH Target Price to HKD 12.5, rating "Outperform".
Citi issued a Research Report stating that it recently met with the management of TRAVELSKY TECH (00696) and gained more insights into its business outlook for the fiscal year 2025. Citi cited the management of China Aviation Information Technology, indicating that there is still uncertainty in the recovery of foreign Airlines this year, which may impede the growth of the Airlines Information Technology (AIT) business. After rapid growth last year, the System Integration (SI) business is expected to show stable performance in fiscal year 2025. The bank has adjusted the Target Price for TRAVELSKY TECH from HKD 13.2 to HKD 12.5, favoring its semi-monopolistic nature and improved dividend policy, maintaining an 'outperform' rating.
Is There An Opportunity With TravelSky Technology Limited's (HKG:696) 49% Undervaluation?
Hong Kong stock market fluctuation | iFlytek Medical Technology (02506) rose over 4% during trading, with the company achieving a year-on-year revenue increase of over 30% for the entire year. The B/C-end Business has shown remarkable high growth.
iFly Medical Technology (02506) rose over 4% during the trading session, and as of the time of writing, it has increased by 2.72%, priced at 128.4 Hong Kong dollars, with a trading volume of 25.2705 million Hong Kong dollars.
Hong Kong stocks in action | TRAVELSKY TECH (00696) rose over 3%, with annual net profit attributable to parent company increasing by nearly 50% year-on-year, driven by strong performances in system integration and other Businesses.
TRAVELSKY TECH (00696) rose over 3%, as of the time of writing, it has increased by 2.32%, trading at 11.46 HKD, with a transaction amount of 47.4085 million HKD.